NO CYTOKINE RELEASE SYNDROME OBSERVED TO DATE EMERYVILLE, Calif., June 4, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of
EMERYVILLE, Calif., January 22, 2018 — Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing
EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T
September 13, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on developing novel T-cell immunotherapies for
POTENTIAL TO ACCELERATE APPLICATION OF CAR-T THERAPY TO OTHER SOLID TUMORS June 07, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. & DUARTE, Calif. -Eureka
April 20, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. -Eureka Therapeutics, Inc., a biotechnology company focused on developing novel T-cell immunotherapies for the treatment
Eureka’s manuscript on targeting alpha-fetoprotein (AFP) with a CAR T cell therapy for the treatment of liver cancer is published in Clinical Cancer Research on August
EMERYVILLE, Calif. & NEW YORK & SEATTLE, Aug 4th, 2016 – Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center(MSK) announced today an exclusive license agreement
EMERYVILLE, CA, Jan. 7th, 2016 – Eureka Therapeutics, Inc. announced today that Memorial Sloan Kettering Cancer Center and Juno Therapeutics, Inc. (Nasdaq: JUNO) have entered into
Eureka’s co-authored paper “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1,” was published on Monday in Nature Biotechnology. The paper describes a bispecific antibody against intracellular antigen
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.